Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
Merck Sharp & Dohme LLC
Modality
UNKNOWN
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
51High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05007106CT.gov MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) | — | Completed | — | — | — |
NCT04585750CT.gov The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | — | Recruiting | — | — | — |
NCT03668418CT.gov Xenotransplantation of Primary Cancer Samples in Zebrafish Embryos | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Gallbladder Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Epirubicin (this asset) | Merck Sharp & Dohme LLC | P2 | BB · 65 |
| Fluorouracilum | Lisata Therapeutics, Inc. | P2 | BBB |
| Capecitabine | Merck Sharp & Dohme LLC | P3 | BB |
| Oxaliplatin | Tianjin Medical University Cancer Institute and Hospital | P3 | BB |
| Cyclophosphamide | Merck Sharp & Dohme LLC | P2 | BB |
| Desflurane | Tokyo Medical and Dental University | P4 | BB |
| Docetaxel | Merck Sharp & Dohme LLC | P2 | BB |
| Sevoflurane | Tokyo Medical and Dental University | P4 | BB |
| Carboplatin | Merck Sharp & Dohme LLC | P2 | BB |
+42 more in the Gallbladder Cancer cohort
Other indications for Epirubicin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Estrogen-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
| Progesterone-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
| Inflammatory Breast Carcinoma | — | P3 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Epirubicin in Gallbladder Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/epirubicin-gallbladder-cancer-116966
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →